

SEATTLE GENETICS INC /WA  
 Form 4  
 May 25, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**SIEGALL CLAY B**

2. Issuer Name and Ticker or Trading Symbol  
**SEATTLE GENETICS INC /WA [SGEN]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 21823 30TH DRIVE SE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 05/23/2016

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 President and CEO

BOTHELL, WA 98021

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V Amount (A) or (D) Price   |   |  |  |
| Common Stock                    | 05/23/2016                           |  | M                              | 6,700 A \$ 10.2   | 562,815 <sup>(1)</sup>  | D  |  |
| Common Stock                    | 05/23/2016                           |  | S <sup>(2)</sup>               | 6,700 D \$ 40.116 <sup>(3)</sup>                                  | 556,115 <sup>(1)</sup>  | D  |  |
| Common Stock                    | 05/24/2016                           |  | M                              | 1,700 A \$ 10.2   | 557,815 <sup>(1)</sup>  | D  |  |
| Common Stock                    | 05/24/2016                           |  | S <sup>(2)</sup>               | 1,700 D \$ 40 <sup>(3)</sup>                                      | 556,115 <sup>(1)</sup>  | D  |  |
| Common Stock                    |                                      |  |                                |   | 27,945  | I  | by Trust                                   |

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Non-Qualified Stock Option (right to buy)  | \$ 10.2  | 05/23/2016                           |  | M                              | 6,700   | <sup>(4)</sup> 05/25/2017                                | Common Stock  | 6,700                      |
| Non-Qualified Stock Option (right to buy)  | \$ 10.2  | 05/24/2016                           |  | M                              | 1,700   | <sup>(4)</sup> 05/25/2017                                | Common Stock  | 1,700                      |

## Reporting Owners

| Reporting Owner Name / Address                              | Relationships |           |                   |       |
|---|---------------|-----------|-------------------|-------|
|   | Director      | 10% Owner | Officer           | Other |
| SIEGALL CLAY B<br>21823 30TH DRIVE SE<br>BOTHHELL, WA 98021 | X             |           | President and CEO |       |

## Signatures

/s/ Clay B. Siegall  
05/25/2016

\*\*Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Amount of securities beneficially owned following the reported transaction(s) include Restricted Stock Units that are subject to vesting.
- (2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

- (3) Sale price represents a weighted average price for all shares sold on this day, which are within a \$1.00 range.
- (4) Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.